Grail files for $100 million IPO
Liquid biopsy mega-player Grail has filed for a $100 million IPO, STAT’s Kate Sheridan writes. The company has already raised around $2 billion from investors, which include Johnson & Johnson and Amazon founder Jeff Bezos, and plans to trade on Nasdaq under the ticker name “GRAL.”
Some interesting new details about the Illumina spinout emerged in the prospectus that detail Grail’s IPO plans. Among them: More than 115,000 people have enrolled in clinical trials to study one of the company’s blood tests, Galleri, which is meant to detect certain cancers.
.png)
No hay comentarios:
Publicar un comentario